Shares of FibroGen Inc (NASDAQ:FGEN) have been given a consensus recommendation of “Buy” by the nine brokerages that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $65.67.
Several brokerages have recently issued reports on FGEN. ValuEngine upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Finally, Mizuho restated a “hold” rating and issued a $61.00 price objective on shares of FibroGen in a research report on Thursday, November 9th.
Shares of FibroGen (NASDAQ:FGEN) traded down $0.60 during trading hours on Tuesday, hitting $50.40. The stock had a trading volume of 580,714 shares, compared to its average volume of 591,460. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen has a twelve month low of $22.75 and a twelve month high of $63.00. The stock has a market capitalization of $4,190.00, a P/E ratio of -25.12 and a beta of 1.74.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.13). FibroGen had a negative net margin of 120.00% and a negative return on equity of 47.36%. sell-side analysts forecast that FibroGen will post -1.75 EPS for the current year.
In related news, insider K Peony Yu sold 10,000 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $62.00, for a total transaction of $620,000.00. Following the transaction, the insider now directly owns 152,086 shares in the company, valued at $9,429,332. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas B. Neff sold 18,900 shares of the stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $46.60, for a total value of $880,740.00. Following the transaction, the chief executive officer now owns 3,109,555 shares in the company, valued at $144,905,263. The disclosure for this sale can be found here. Insiders have sold 328,917 shares of company stock worth $16,142,651 over the last quarter. 13.60% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FGEN. Lee Financial Co purchased a new position in shares of FibroGen in the 4th quarter worth about $347,000. State of Wisconsin Investment Board raised its holdings in shares of FibroGen by 50.0% in the 4th quarter. State of Wisconsin Investment Board now owns 66,000 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 22,000 shares during the period. BBR Partners LLC raised its holdings in shares of FibroGen by 18.0% in the 4th quarter. BBR Partners LLC now owns 6,556 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 1,000 shares during the period. BHK Investment Advisors LLC purchased a new position in shares of FibroGen in the 4th quarter worth about $654,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of FibroGen by 5.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 53,197 shares of the biopharmaceutical company’s stock worth $2,521,000 after purchasing an additional 2,872 shares during the period. Hedge funds and other institutional investors own 57.11% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/16/fibrogen-inc-fgen-receives-65-67-consensus-target-price-from-brokerages.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.